SCHEMBL24254492

SCHEMBL24254492

Cc1ccc(S(=O)(=O)N(C)C)cc1C(=O)NCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.61
SMN1; SMN2 Q16637 4/20 0.57
ALDH1A1 P00352 7/20 0.56
HPGD P15428 1/20 0.50
LMNA P02545 2/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 2/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
ATM Q13315 1/20 0.47
TSHR P16473 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GAA P10253 1/20 0.47
APEX1 P27695 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26188331 0.88 NPC1 (0.53) NPC1SMN1; SMN2ALDH1A1HPGDLMNA
SCHEMBL24254487 0.85 NPC1 (0.54) NPC1SMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL26188327 0.83 ALDH1A1 (0.55) NPC1SMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL24254574 0.78 HPGD (0.51) SMN1; SMN2ALDH1A1HPGDLMNAKMT2A
SCHEMBL8301665 0.77 NPC1 (0.52) NPC1SMN1; SMN2ALDH1A1HPGDLMNA
SCHEMBL24254502 0.75 ALDH1A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHTT
SCHEMBL26188116 0.74 EPHX2 (0.61) ALDH1A1HPGDLMNAHTTKMT2A
SCHEMBL24254493 0.73 CYP3A4 (0.50) ALDH1A1LMNAMAPTHTTKMT2A
SCHEMBL29334953 0.72 LMNA (0.57) ALDH1A1HPGDLMNAKMT2AMEN1
SCHEMBL11179145 0.72 SMN1; SMN2 (0.54) NPC1SMN1; SMN2ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 NPC1 2293/4885SMN1; SMN2 2091/4885ALDH1A1 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.